Neuralink Submits First Peer-Reviewed Paper with Human Trial Data to The New England Journal of Medicine

For stock trading, look atJin Qilin Analyst Research Report, authoritative, professional, timely, comprehensive, helping you uncover potential thematic opportunities!

(Source: IT Home)

IT Home, October 5 – Neuralink, the brain-computer interface company under Elon Musk, has submitted its first academic paper containing safety data from its human trials to The New England Journal of Medicine, providing updates on the status of its first three participants.

This information comes from Michael Lawton, CEO and President of the Barrow Neurological Institute, one of Neuralink’s clinical trial sites. Lawton disclosed the information on the sidelines of a brain implant conference hosted by the Mount Sinai Health System in New York but declined to provide further details. According to previously disclosed data, Neuralink has currently implanted devices in 12 participants.

Neuralink Corp has raised over $1 billion in funding to date (IT Home note: approximately RMB 7.128 billion at the current exchange rate), with its latest funding round valuing the company at $9 billion, but it has yet to publish peer-reviewed human trial data.

Neuralink President DJ Seo stated in September that the company aims to implant its brain-computer interface devices in healthy individuals by 2030. Currently, brain-computer interfaces are primarily used experimentally to help critically ill patients control computers.

Lawton pointed out that the company “envisions providing this technology to nearly anyone who might need it,” but there is still a long way to go before it can be applied to healthy individuals. “They have been very cautious, focusing on patients with disabilities.”

Neuralink aims to implant chips in 20,000 patients annually by 2031 and achieve annual revenue of at least $1 billion. In addition to helping patients control computers, the company is developing chips capable of restoring vision, decoding language from the brain, and treating Parkinson’s disease.